219 related articles for article (PubMed ID: 36053960)
41. Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management.
Dandurand K; Ali DS; Khan AA
J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33918966
[TBL] [Abstract][Full Text] [Related]
42. Primary hyperparathyroidism and the skeleton.
Mosekilde L
Clin Endocrinol (Oxf); 2008 Jul; 69(1):1-19. PubMed ID: 18167138
[TBL] [Abstract][Full Text] [Related]
43. Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society.
Milat F; Ramchand SK; Herath M; Gundara J; Harper S; Farrell S; Girgis CM; Clifton-Bligh R; Schneider HG; De Sousa SMC; Gill AJ; Serpell J; Taubman K; Christie J; Carroll RW; Miller JA; Grossmann M
Clin Endocrinol (Oxf); 2024 Jan; 100(1):3-18. PubMed ID: 34931708
[TBL] [Abstract][Full Text] [Related]
44. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
Sayed SA; El Wakeel LM; Elseasi AM; Shawki MA
Pharmacotherapy; 2023 Sep; 43(9):904-912. PubMed ID: 37323099
[TBL] [Abstract][Full Text] [Related]
46. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Leere JS; Karmisholt J; Robaczyk M; Lykkeboe S; Handberg A; Steinkohl E; Brøndum Frøkjær J; Vestergaard P
Lancet Diabetes Endocrinol; 2020 May; 8(5):407-417. PubMed ID: 32333877
[TBL] [Abstract][Full Text] [Related]
47. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism.
Lewiecki EM
J Clin Densitom; 2010; 13(4):324-34. PubMed ID: 21029971
[TBL] [Abstract][Full Text] [Related]
48. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
49. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
50. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
51. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
52. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
53. Management of Hypoparathyroidism.
Khan AA; Guyatt G; Ali DS; Bilezikian JP; Collins MT; Dandurand K; Mannstadt M; Murphy D; M'Hiri I; Rubin MR; Sanders R; Shrayyef M; Siggelkow H; Tabacco G; Tay YD; Van Uum S; Vokes T; Winer KK; Yao L; Rejnmark L
J Bone Miner Res; 2022 Dec; 37(12):2663-2677. PubMed ID: 36161671
[TBL] [Abstract][Full Text] [Related]
54. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
55. Medical management of primary hyperparathyroidism.
Khan AA
J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
Manaka K; Sato J; Kinoshita Y; Ito N; Fujita M; Iiri T; Nangaku M; Makita N
Endocr J; 2019 Aug; 66(8):683-689. PubMed ID: 31092749
[TBL] [Abstract][Full Text] [Related]
57. Mild primary hyperparathyroidism-to treat or not to treat?
Hassan-Smith ZK; Criseno S; Gittoes NJL
Br Med Bull; 2019 Mar; 129(1):53-67. PubMed ID: 30576424
[TBL] [Abstract][Full Text] [Related]
58. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
59. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
60. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics].
Brardi S; Ponchietti R; Duranti E
G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
